US20190117466A1 - Area management of tissue sites on articulating joints - Google Patents

Area management of tissue sites on articulating joints Download PDF

Info

Publication number
US20190117466A1
US20190117466A1 US16/166,424 US201816166424A US2019117466A1 US 20190117466 A1 US20190117466 A1 US 20190117466A1 US 201816166424 A US201816166424 A US 201816166424A US 2019117466 A1 US2019117466 A1 US 2019117466A1
Authority
US
United States
Prior art keywords
dressing
arm
manifold
stem
pressure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US16/166,424
Other languages
English (en)
Inventor
Richard Marvin Kazala, JR.
Larry Tab Randolph
Luke Perkins
Enrique L. SANDOVAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Solventum Intellectual Properties Co
Original Assignee
KCI Licensing Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KCI Licensing Inc filed Critical KCI Licensing Inc
Priority to US16/166,424 priority Critical patent/US20190117466A1/en
Publication of US20190117466A1 publication Critical patent/US20190117466A1/en
Assigned to KCI LICENSING, INC. reassignment KCI LICENSING, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KAZALA, RICHARD MARVIN, PERKINS, LUKE, RANDOLPH, LARRY TAB, SANDOVAL, Enrique L.
Assigned to 3M INNOVATIVE PROPERTIES COMPANY reassignment 3M INNOVATIVE PROPERTIES COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KCI LICENSING, INC.
Assigned to 3M INNOVATIVE PROPERTIES COMPANY reassignment 3M INNOVATIVE PROPERTIES COMPANY CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION LISTED ON SCHEDULE OF IP RIGHTS ATTACHED TO ASSIGNMENT AT LINES 55: 71; 89; 116-129; AND 131 NEED TO BE DELETED PREVIOUSLY RECORDED AT REEL: 064788 FRAME: 0823. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Assignors: KCI LICENSING, INC.
Assigned to SOLVENTUM INTELLECTUAL PROPERTIES COMPANY reassignment SOLVENTUM INTELLECTUAL PROPERTIES COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: 3M INNOVATIVE PROPERTIES COMPANY
Pending legal-status Critical Current

Links

Images

Classifications

    • A61F13/00068—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/05—Bandages or dressings; Absorbent pads specially adapted for use with sub-pressure or over-pressure therapy, wound drainage or wound irrigation, e.g. for use with negative-pressure wound therapy [NPWT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B46/00—Surgical drapes
    • A61B46/20—Surgical drapes specially adapted for patients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/06—Bandages or dressings; Absorbent pads specially adapted for feet or legs; Corn-pads; Corn-rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/425—Porous materials, e.g. foams or sponges
    • A61M1/0088—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/71—Suction drainage systems
    • A61M1/74—Suction control
    • A61M1/75—Intermittent or pulsating suction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
    • A61M1/91—Suction aspects of the dressing
    • A61M1/915—Constructional details of the pressure distribution manifold
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
    • A61M1/91—Suction aspects of the dressing
    • A61M1/917—Suction aspects of the dressing specially adapted for covering whole body parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
    • A61M1/96—Suction control thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B46/00—Surgical drapes
    • A61B46/20—Surgical drapes specially adapted for patients
    • A61B2046/205—Adhesive drapes
    • A61F13/0216—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00089—Wound bandages
    • A61F2013/0017—Wound bandages possibility of applying fluid
    • A61F2013/00174—Wound bandages possibility of applying fluid possibility of applying pressure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/08—Limbs
    • A61M2210/086—Legs

Definitions

  • the invention set forth in the appended claims relates generally to tissue treatment systems and more particularly, but without limitation, to area management of incisions and other tissue sites on articulating joints.
  • Negative-pressure therapy may provide a number of benefits, including migration of epithelial and subcutaneous tissues, improved blood flow, and micro-deformation of tissue at a wound site. Together, these benefits can increase development of granulation tissue and reduce healing times.
  • such an apparatus may be a dressing for managing an incision and surrounding tissue where edema and swelling may be present post-operation.
  • the dressing may maximize coverage of area in articulating joints, such as a knee or elbow, while allowing for substantial range of motion.
  • the dressing may comprise an adhesive border configured to be adhered to skin around an articulating joint, a skin-interfacing fabric for minimizing skin irritation, a foam body for manifolding negative pressure and absorbing exudate and other body fluids, and a thin polymer film cap for sealing the assembly so negative pressure can be maintained throughout the dressing.
  • the dressing may have one or more portions which can be cut to customize the size of the dressing. Separate adhesive films can be applied over the cut portions for sealing.
  • a dressing for treating an area around an articulating joint may comprise an attachment device, such as a sealing ring, having a treatment aperture; a manifold comprising a stem, a first arm joined to the stem, and a second arm joined to the stem; a cover disposed over the manifold and coupled to the attachment device around the manifold; and an adhesive on the attachment device configured to bond to the area around the articulating joint.
  • the manifold may be at least partially exposed through the treatment aperture.
  • the manifold may comprise a first arm having a greater span than the second arm.
  • the first arm and the second arm may flare away from the stem in some embodiments.
  • the manifold may comprise a face that is biconcave in some embodiments.
  • the stem, the first arm, and the second arm may define a concave void on opposing sides of the manifold.
  • the dressing may comprise a manifold having a first portion configured to be disposed over an articulating surface of a limb; a second portion configured to be at least partially wrapped around a proximal portion of the limb; and a third portion configured to be at least partially wrapped around a distal portion of the limb.
  • the first portion may be positioned over a knee.
  • the dressing may have an opening or void on each side of the first portion between the second portion and the third portion.
  • the second portion and the third portion may have converging edges.
  • the second portion and the third portion may flare away from a midline of the first portion.
  • An example method of treating an area around an articulating joint of a limb may comprise applying the dressing so that a stem of the dressing is disposed over the articulating joint; wrapping a first arm of the dressing around a proximal portion of the limb; wrapping a second arm around a distal portion of the limb; fluidly coupling a negative-pressure source to the manifold; and applying negative-pressure from the negative-pressure source.
  • FIG. 1 is a functional block diagram of an example embodiment of a therapy system that can provide negative-pressure treatment in accordance with this specification;
  • FIG. 2 is a graph illustrating additional details of example pressure control modes that may be associated with some embodiments of the therapy system of FIG. 1 ;
  • FIG. 3 is a graph illustrating additional details that may be associated with another example pressure control mode in some embodiments of the therapy system of FIG. 1 ;
  • FIG. 4 is a top view of a dressing illustrating additional details that may be associated with an example embodiment of therapy system of FIG. 1 ;
  • FIG. 5 is an assembly view of the dressing of FIG. 4 , illustrating additional details that may be associated with some examples;
  • FIG. 6 is a top view of another example of the dressing, illustrating additional details that may be associated with some embodiments.
  • FIG. 7 illustrates the dressing of FIG. 4 applied to an articulating joint.
  • FIG. 1 is a simplified functional block diagram of an example embodiment of a therapy system 100 that can provide negative-pressure therapy to a tissue site in accordance with this specification.
  • tissue site in this context broadly refers to a wound, defect, or other treatment target located on or within tissue, including but not limited to, bone tissue, adipose tissue, muscle tissue, neural tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, or ligaments.
  • a wound may include chronic, acute, traumatic, subacute, and dehisced wounds, partial-thickness burns, ulcers (such as diabetic, pressure, or venous insufficiency ulcers), flaps, and grafts, for example.
  • tissue site may also refer to areas of any tissue that are not necessarily wounded or defective, but are instead areas in which it may be desirable to add or promote the growth of additional tissue. For example, negative pressure may be applied to a tissue site to grow additional tissue that may be harvested and transplanted.
  • the therapy system 100 may include a source or supply of negative pressure, such as a negative-pressure source 105 , a dressing 110 , a fluid container, such as a container 115 , and a regulator or controller, such as a controller 120 , for example. Additionally, the therapy system 100 may include sensors to measure operating parameters and provide feedback signals to the controller 120 indicative of the operating parameters. As illustrated in FIG. 1 , for example, the therapy system 100 may include one or more sensors coupled to the controller 120 , such as a first sensor 125 and a second sensor 130 . As illustrated in the example of FIG. 1 , the dressing 110 may comprise or consist essentially of a tissue interface 135 , a cover 140 , or both in some embodiments.
  • Some components of the therapy system 100 may be housed within or used in conjunction with other components, such as sensors, processing units, alarm indicators, memory, databases, software, display devices, or user interfaces that further facilitate therapy.
  • the negative-pressure source 105 may be combined with the controller 120 and other components into a therapy unit.
  • components of the therapy system 100 may be coupled directly or indirectly.
  • the negative-pressure source 105 may be directly coupled to the container 115 , and may be indirectly coupled to the dressing 110 through the container 115 .
  • Coupling may include fluid, mechanical, thermal, electrical, or chemical coupling (such as a chemical bond), or some combination of coupling in some contexts.
  • the negative-pressure source 105 may be electrically coupled to the controller 120 , and may be fluidly coupled to one or more distribution components to provide a fluid path to a tissue site.
  • components may also be coupled by virtue of physical proximity, being integral to a single structure, or being formed from the same piece of material.
  • a distribution component is preferably detachable, and may be disposable, reusable, or recyclable.
  • the dressing 110 and the container 115 are illustrative of distribution components.
  • a fluid conductor is another illustrative example of a distribution component.
  • a tube is an elongated, cylindrical structure with some flexibility, but the geometry and rigidity may vary.
  • some fluid conductors may be molded into or otherwise integrally combined with other components.
  • Distribution components may also include or comprise interfaces or fluid ports to facilitate coupling and de-coupling other components.
  • a dressing interface may facilitate coupling a fluid conductor to the dressing 110 .
  • such a dressing interface may be a SENSAT.R.A.C.TM Pad available from KCI of San Antonio, Tex.
  • a negative-pressure supply such as the negative-pressure source 105
  • Negative pressure generally refers to a pressure less than a local ambient pressure, such as the ambient pressure in a local environment external to a sealed therapeutic environment. In many cases, the local ambient pressure may also be the atmospheric pressure at which a tissue site is located. Alternatively, the pressure may be less than a hydrostatic pressure associated with tissue at the tissue site. Unless otherwise indicated, values of pressure stated herein are gauge pressures.
  • references to increases in negative pressure typically refer to a decrease in absolute pressure, while decreases in negative pressure typically refer to an increase in absolute pressure.
  • the pressure is generally a low vacuum, also commonly referred to as a rough vacuum, between ⁇ 5 mm Hg ( ⁇ 667 Pa) and ⁇ 500 mm Hg ( ⁇ 66.7 kPa).
  • Common therapeutic ranges are between ⁇ 50 mm Hg ( ⁇ 6.7 kPa) and ⁇ 300 mm Hg ( ⁇ 39.9 kPa).
  • the container 115 is representative of a container, canister, pouch, or other storage component, which can be used to manage exudates and other fluids withdrawn from a tissue site.
  • a rigid container may be preferred or required for collecting, storing, and disposing of fluids.
  • fluids may be properly disposed of without rigid container storage, and a re-usable container could reduce waste and costs associated with negative-pressure therapy.
  • a controller such as the controller 120
  • the controller 120 may be a microcontroller, which generally comprises an integrated circuit containing a processor core and a memory programmed to directly or indirectly control one or more operating parameters of the therapy system 100 . Operating parameters may include the power applied to the negative-pressure source 105 , the pressure generated by the negative-pressure source 105 , or the pressure distributed to the tissue interface 135 , for example.
  • the controller 120 is also preferably configured to receive one or more input signals, such as a feedback signal, and programmed to modify one or more operating parameters based on the input signals.
  • Sensors such as the first sensor 125 and the second sensor 130 , are generally known in the art as any apparatus operable to detect or measure a physical phenomenon or property, and generally provide a signal indicative of the phenomenon or property that is detected or measured.
  • the first sensor 125 and the second sensor 130 may be configured to measure one or more operating parameters of the therapy system 100 .
  • the first sensor 125 may be a transducer configured to measure pressure in a pneumatic pathway and convert the measurement to a signal indicative of the pressure measured.
  • the first sensor 125 may be a piezoresistive strain gauge.
  • the second sensor 130 may optionally measure operating parameters of the negative-pressure source 105 , such as the voltage or current, in some embodiments.
  • the signals from the first sensor 125 and the second sensor 130 are suitable as an input signal to the controller 120 , but some signal conditioning may be appropriate in some embodiments.
  • the signal may need to be filtered or amplified before it can be processed by the controller 120 .
  • the signal is an electrical signal, but may be represented in other forms, such as an optical signal.
  • the tissue interface 135 can be generally adapted to partially or fully contact a tissue site.
  • the tissue interface 135 may take many forms, and may have many sizes, shapes, or thicknesses depending on a variety of factors, such as the type of treatment being implemented or the nature and size of a tissue site.
  • the size and shape of the tissue interface 135 may be adapted to the contours of deep and irregular shaped tissue sites.
  • any or all of the surfaces of the tissue interface 135 may have projections or an uneven, course, or jagged profile that can induce strains and stresses on a tissue site, which can promote granulation at the tissue site.
  • the tissue interface 135 may be a manifold.
  • a “manifold” in this context generally includes any substance or structure providing a plurality of pathways adapted to collect or distribute fluid across a tissue site under pressure.
  • a manifold may be adapted to receive negative pressure from a source and distribute negative pressure through multiple apertures across a tissue site, which may have the effect of collecting fluid from across a tissue site and drawing the fluid toward the source.
  • the fluid path may be reversed or a secondary fluid path may be provided to facilitate delivering fluid across a tissue site.
  • a manifold may be a porous foam material having interconnected cells or pores.
  • open-cell foam, porous tissue collections, and other porous material such as gauze or felted mat generally include pores, edges, and/or walls adapted to form interconnected fluid channels.
  • Liquids, gels, and other foams may also include or be cured to include apertures and fluid pathways.
  • a manifold may additionally or alternatively comprise projections that form interconnected fluid pathways.
  • a manifold may be molded to provide surface projections that define interconnected fluid pathways.
  • the average pore size of foam may vary according to needs of a prescribed therapy.
  • the tissue interface 135 may be foam having pore sizes in a range of 400-600 microns.
  • the tensile strength of the tissue interface 135 may also vary according to needs of a prescribed therapy. For example, the tensile strength of foam may be increased for instillation of topical treatment solutions.
  • the tissue interface 135 may be reticulated polyurethane foam such as found in GRANUFOAMTM dressing or V.A.C. VERAFLOTM dressing, both available from KCI of San Antonio, Tex.
  • the tissue interface 135 may be either hydrophobic or hydrophilic. In an example in which the tissue interface 135 may be hydrophilic, the tissue interface 135 may also wick fluid away from a tissue site, while continuing to distribute negative pressure to the tissue site. The wicking properties of the tissue interface 135 may draw fluid away from a tissue site by capillary flow or other wicking mechanisms.
  • An example of hydrophilic foam is a polyvinyl alcohol, open-cell foam such as V.A.C. WHITEFOAMTM dressing available from KCI of San Antonio, Tex. Other hydrophilic foams may include those made from polyether. Other foams that may exhibit hydrophilic characteristics include hydrophobic foams that have been treated or coated to provide hydrophilicity.
  • the tissue interface 135 may further promote granulation at a tissue site when pressure within the sealed therapeutic environment is reduced.
  • any or all of the surfaces of the tissue interface 135 may have an uneven, coarse, or jagged profile that can induce microstrain and stress at a tissue site if negative pressure is applied through the tissue interface 135 .
  • the tissue interface 135 may be constructed from bioresorbable materials. Suitable bioresorbable materials may include, without limitation, a polymeric blend of polylactic acid (PLA) and polyglycolic acid (PGA). The polymeric blend may also include without limitation polycarbonates, polyfumarates, and capralactones.
  • the tissue interface 135 may further serve as a scaffold for new cell-growth, or a scaffold material may be used in conjunction with the tissue interface 135 to promote cell-growth.
  • a scaffold is generally a substance or structure used to enhance or promote the growth of cells or formation of tissue, such as a three-dimensional porous structure that provides a template for cell growth.
  • Illustrative examples of scaffold materials include calcium phosphate, collagen, PLA/PGA, coral hydroxy apatites, carbonates, or processed allograft materials.
  • the cover 140 may provide a bacterial barrier and protection from physical trauma.
  • the cover 140 may also be constructed from a material that can reduce evaporative losses and provide a fluid seal between two components or two environments, such as between a therapeutic environment and a local external environment.
  • the cover 140 may comprise or consist essentially of an elastomeric film or membrane that can provide a seal adequate to maintain a negative pressure at a tissue site for a given negative-pressure source.
  • the cover 140 may be a polymer drape, such as a polyurethane film, that is permeable to water vapor but impermeable to liquid.
  • the cover 140 may have a high moisture-vapor transmission rate (MVTR) in some applications.
  • MVTR moisture-vapor transmission rate
  • the MVTR may be at least 250 g/m ⁇ 2 per twenty-four hours in some embodiments (based on ASTM E96/E96M for upright cup measurement).
  • Such drapes typically have a thickness in the range of 25-50 microns.
  • the permeability generally should be low enough that a desired negative pressure may be maintained.
  • An attachment device may be used to attach the cover 140 to an attachment surface, such as undamaged epidermis, a gasket, or another cover.
  • the attachment device may take many forms.
  • an attachment device may be a medically-acceptable, pressure-sensitive adhesive configured to bond the cover 140 to epidermis around a tissue site.
  • some or all of the cover 140 may be coated with an adhesive, such as an acrylic adhesive, which may have a coating weight between 25-65 grams per square meter (g.s.m.). Thicker adhesives, or combinations of adhesives, may be applied in some embodiments to improve the seal and reduce leaks.
  • Other example embodiments of an attachment device may include a double-sided tape, paste, hydrocolloid, hydrogel, silicone gel, or organogel.
  • FIG. 2 is a graph illustrating additional details of an example control mode that may be associated with some embodiments of the controller 120 .
  • the controller 120 may have a continuous pressure mode, in which the negative-pressure source 105 is operated to provide a constant target negative pressure, as indicated by line 205 and line 210 , for the duration of treatment or until manually deactivated. Additionally or alternatively, the controller may have an intermittent pressure mode, as illustrated in the example of FIG. 2 .
  • the x-axis represents time
  • the y-axis represents negative pressure generated by the negative-pressure source 105 over time.
  • the controller 120 can operate the negative-pressure source 105 to cycle between a target pressure and atmospheric pressure.
  • the target pressure may be set at a value of 125 mmHg, as indicated by line 205 , for a specified period of time (e.g., 5 min), followed by a specified period of time (e.g., 2 min) of deactivation, as indicated by the gap between the solid lines 215 and 220 .
  • the cycle can be repeated by activating the negative-pressure source 105 , as indicated by line 220 , which can form a square wave pattern between the target pressure and atmospheric pressure.
  • the increase in negative-pressure from ambient pressure to the target pressure may not be instantaneous.
  • the negative-pressure source 105 and the dressing 110 may have an initial rise time, as indicated by the dashed line 225 .
  • the initial rise time may vary depending on the type of dressing and therapy equipment being used.
  • the initial rise time for one therapy system may be in a range of about 20-30 mmHg/second and in a range of about 5-10 mmHg/second for another therapy system.
  • the repeating rise time as indicated by the solid line 220 may be a value substantially equal to the initial rise time as indicated by the dashed line 225 .
  • FIG. 3 is a graph illustrating additional details that may be associated with another example pressure control mode in some embodiments of the therapy system 100 .
  • the x-axis represents time and the y-axis represents negative pressure generated by the negative-pressure source 105 .
  • the target pressure in the example of FIG. 3 can vary with time in a dynamic pressure mode.
  • the target pressure may vary in the form of a triangular waveform, varying between a minimum and maximum negative pressure of 50-125 mmHg with a rise time 305 set at a rate of +25 mmHg/min. and a descent time 310 set at ⁇ 25 mmHg/min, respectively.
  • the triangular waveform may vary between negative pressure of 25-125 mmHg with a rise time 305 set at a rate of +30 mmHg/min and a descent time 310 set at ⁇ 30 mmHg/min.
  • the controller 120 may control or determine a variable target pressure in a dynamic pressure mode, and the variable target pressure may vary between a maximum and minimum pressure value that may be set as an input prescribed by an operator as the range of desired negative pressure.
  • the variable target pressure may also be processed and controlled by the controller 120 , which can vary the target pressure according to a predetermined waveform, such as a triangular waveform, a sine waveform, or a saw-tooth waveform.
  • the waveform may be set by an operator as the predetermined or time-varying negative pressure desired for therapy.
  • FIG. 4 is a top view of an example of the dressing 110 , illustrating additional details that may be associated with some embodiments.
  • the dressing 110 includes features that can cover articulating joints, such as a knee, while still allowing for significant range of motion.
  • the dressing 110 of FIG. 4 generally comprises a manifold 405 having a stem 410 , a first arm 415 joined to a first end of the stem 410 , and a second arm 420 joined to a second end of the stem 410 .
  • the manifold 405 may be characterized as a polyhedron or as a generalized cylinder.
  • the manifold 405 can be characterized as a generalized cylinder having a face 425 and an edge 430 .
  • the edge 430 in FIG. 4 bounds the stem 410 , the first arm 415 , and the second arm 420 .
  • some portions of the edge 430 may be curved, and some portions may be straight.
  • the first arm 415 is bounded in part by a first edge portion 435 that is substantially straight
  • the second arm 420 is bounded in part by a second edge portion 440 that is substantially straight.
  • the first arm 415 , the second arm 420 , or both may be contoured at the extremities.
  • the stem 410 is generally configured to be positioned over an articular surface.
  • the width of the stem 410 may vary for different types of joints, and may be limited to minimize interference with articulation.
  • the stem 410 may be configured for positioning over a patella and have a width of 2-4 inches. In other examples, a width of 1-3 inches may be suitable for positioning over an olecranon.
  • the first arm 415 and the second arm 420 may flare away from the stem 410 .
  • the face 425 may be biconcave. More generally, portions of the edge 430 bounding the first arm 415 and the second arm 420 may converge toward the stem 410 to define a concave void adjacent to each side of the stem 410 . In the example of FIG. 4 , the concave void is curved. In other examples, the edge 430 may have straight segments that converge toward a vertex at the stem 410 .
  • manifold 405 may additionally be characterized by a line of symmetry 445 through the stem 410 , and each of the first arm 415 and the second arm 420 may be characterized by a span that is generally orthogonal to the line of symmetry 445 .
  • a first span 450 between extremities 455 is characteristic of the first arm 415
  • a second span 460 between extremities 465 is characteristic of the second arm 420 .
  • the first span 450 is greater than the second span 460 .
  • a suitable ratio of the span of the first span 450 to the second span 460 may generally be in a range of 1.2 to 3.4.
  • a ratio of 1.2 to 1.6 may be particularly advantageous for some applications.
  • the first span 450 may be in a range of 30-65 centimeters and the second span 460 may be in a range of 20-45 centimeters.
  • the first span 450 may be in a range of 15-50 centimeters and the second span 460 may be in a range of 8-25 centimeters.
  • a fluid conductor 470 may be coupled to the dressing 110 . As illustrated in FIG. 4 , the fluid conductor 470 may be coupled to the first arm 415 . FIG. 4 also illustrates an example of a dressing interface 475 that may be used to facilitate fluidly coupling the fluid conductor 470 to the manifold 405 .
  • FIG. 5 is an assembly view of the dressing 110 of FIG. 4 , illustrating additional details that may be associated with some examples.
  • the cover 140 , the manifold 405 , an adhesive ring 505 , and an attachment device 510 with a treatment area aperture 515 are disposed in a stacked relationship.
  • the cover 140 , the manifold 405 , the adhesive ring 505 , and the attachment device 510 of FIG. 5 have similar shapes.
  • the attachment device 510 may be slightly larger than the manifold 405 , and the adhesive ring 505 can bond a peripheral portion of the manifold 405 to an interior portion of the attachment device 510 .
  • the manifold 405 can be exposed through the treatment area aperture 515 .
  • an adhesive may be disposed on at least portions of the manifold 405 exposed through the treatment area aperture 515 .
  • portions of the first arm 415 , the second arm 420 , or both may have an adhesive coating.
  • the adhesive may be pattern-coated, and may cover up to 50% of the surface.
  • the dressing 110 may optionally include one or more release liners, such as a center release liner 520 , a first side release liner 525 , and a second side release liner 530 .
  • the dressing 110 may have two release liners, each of which may have perforations or slits configured to allow the release liners to be separated into smaller pieces for removal. Additionally, some embodiments may also have one or more casting sheet liners 535 .
  • the attachment device 510 may be a sealing ring. Similar or analogous to the cover 140 , a suitable sealing ring may be, for example, an elastomeric film or membrane that can provide a seal in a therapeutic negative-pressure environment.
  • the attachment device 510 may be a polymer film, such as a polyurethane film, that is permeable to water vapor but impermeable to liquid.
  • the attachment device 510 typically has a thickness in the range of 25-50 microns. For permeable materials, the permeability generally should be low enough that a desired negative pressure may be maintained.
  • the attachment device 510 may also include a medically-acceptable, pressure-sensitive adhesive.
  • the attachment device 510 may be a polymer film coated with an adhesive, such as an acrylic adhesive, which may have a coating weight between 25-65 grams per square meter (g.s.m.). Thicker adhesives, or combinations of adhesives, may be applied in some embodiments to improve the seal and reduce leaks. Additionally or alternatively, the attachment device 510 may comprise a hydrocolloid adhesive, which can substantially reduce or prevent skin irritation.
  • an adhesive such as an acrylic adhesive, which may have a coating weight between 25-65 grams per square meter (g.s.m.). Thicker adhesives, or combinations of adhesives, may be applied in some embodiments to improve the seal and reduce leaks.
  • the attachment device 510 may comprise a hydrocolloid adhesive, which can substantially reduce or prevent skin irritation.
  • some embodiments of the manifold 405 may have flexibility notches 540 .
  • the flexibility notches 540 may be parallel to the line of symmetry 445 , perpendicular to the line of symmetry 445 , or both. Additionally or alternatively, one or more of the flexibility notches 540 may be oblique to the line of symmetry 445 .
  • only the stem 410 may have the flexibility notches 540 .
  • only the first arm 415 , the second arm 420 , or both may have the flexibility notches 540 .
  • the thickness of the manifold 405 may vary according to prescribed therapy.
  • the manifold 405 or some portion of the manifold 405 may comprise felted, open-cell foam to increase rigidity.
  • the manifold 405 may comprise foam segments having different density.
  • the stem 410 may comprise or consist essentially of open-cell foam having a higher density than the first arm 415 and the second arm 420 .
  • the cover 140 may be larger than the manifold 405 , as illustrated in the example of FIG. 5 , and may have a perimeter configured to be attached to the attachment device 510 .
  • the cover 140 may have a flange 545 . Assembled, the cover 140 may be disposed over the face 425 , and the flange 545 may be attached to the attachment device 510 around the manifold 405 .
  • an adhesive may be used to adhere the flange 545 to the attachment device 510 , or the flange 545 may be welded, stitched, or stapled to the attachment device 510 .
  • the cover 140 also has an aperture 550 and an expansion zone 555 in the example of FIG. 5 .
  • the aperture 550 can allow fluid communication between the manifold 405 and a dressing interface or fluid conductor.
  • the expansion zone 555 may comprise folds, ribs, bellows, or other means for allowing the cover 140 to expand if needed.
  • the dressing 110 may additionally include a comfort layer (not shown) coupled to the manifold and at least partially exposed through the treatment area aperture 515 .
  • the comfort layer may comprise or consist essentially of a material that substantially reduces or eliminates skin irritation while allowing fluid transfer through the comfort layer. Examples of materials that may be suitable include woven or non-woven textiles and fenestrated polymer films.
  • the center release liner 520 , the first side release liner 525 , and the second side release liner 530 may cover any adhesive on the attachment device 510 . Additionally or alternatively, the center release liner 520 , the first side release liner 525 , and the second side release liner 530 may provide stiffness to the attachment device 510 to facilitate handling and application. Additionally or alternatively, the casting sheet liners 535 may cover the flange 545 to provide stiffness to the cover 140 for handling and application.
  • FIG. 6 is a top view of another example of the dressing 110 , illustrating additional details that may be associated with some embodiments.
  • the dressing 110 of FIG. 6 is similar the dressing 110 of FIG. 4 in many respects.
  • the face 425 of the dressing 110 of FIG. 6 may be biconcave. More generally, portions of the edge 430 bounding the first arm 415 and the second arm 420 may converge toward the stem 410 to define a concave void adjacent to each side of the stem 410 .
  • the manifold 405 may additionally be characterized by a line of symmetry 605 through the stem 410 , and each of the first arm 415 and the second arm 420 may be characterized by a span that is generally parallel to the line of symmetry 605 .
  • the first span 450 and the second span 460 are substantially equal.
  • the stem 410 in the example of FIG. 6 is offset from a center of the first span 450 and the second span 460 .
  • the first arm 415 and the second arm 420 each have a sacrificial extension portion 610 on one side of the stem 410 .
  • the manifold 405 may have distinct pressure zones.
  • the stem 410 may be fluidly isolated from the first arm 415 , the second arm 420 , or both.
  • Each pressure zone may have a distinct fluid interface in some embodiments.
  • the cover 140 , the manifold 405 , the attachment device 510 , or various combinations may be assembled before application or in situ.
  • the dressing 110 may be provided as a single unit.
  • the center release liner 520 may be removed from the dressing 110 , exposing a portion of the attachment device 510 .
  • the manifold 405 may be placed within, over, on, or otherwise proximate to a tissue site, and the exposed portion of the attachment device 510 may be placed against epidermis adjacent to the tissue site. If the tissue site is an incision, for example, the manifold 405 may be placed over the incision. In some embodiments, the line of symmetry 445 may be aligned with some or all of the incision. If the tissue site is on a limb, the first arm 415 may be wrapped around a proximal portion of the limb and the second arm 420 may be wrapped around a distal portion of the limb.
  • the first arm 415 and the second arm 420 may not directly contact the incision in some applications, and a stronger adhesive may be used to secure at least portions of the first arm 415 and the second arm 420 to epidermis adjacent to the incision.
  • the first side release liner 525 and the second side release liner 530 may be removed and applied to additional epidermis adjacent to the tissue site.
  • the dressing 110 can provide a sealed therapeutic environment proximate to a tissue site, substantially isolated from the external environment, and the negative-pressure source 105 can be fluidly coupled to the manifold 405 through the aperture 550 .
  • FIG. 7 illustrates the dressing 110 of FIG. 4 applied to an incision (not shown) on an articulating joint.
  • the articulating joint is a knee 705 .
  • the stem 410 may substantially cover the top of the knee 705 .
  • the manifold 405 is preferably oriented so that the first arm 415 and the fluid conductor 470 are superior to the knee 705 .
  • the first arm 415 may cover and wrap around a portion of the leg superior to the knee 705
  • the second arm 420 may cover and wrap around a portion of the leg inferior to the knee 705 .
  • one or more of the first arm 415 and the second arm 420 may be cut to reduce the first span 450 , the second span 460 , or both.
  • the extension portion 610 of the first arm 415 , the second arm 420 , or both may be cut so that the first arm 415 and the second arm 420 can fully wrap a portion of the leg superior and inferior to the knee 705 , respectively.
  • the negative-pressure source 105 can reduce pressure in the sealed therapeutic environment. Negative pressure applied across the tissue site through the manifold 405 in the sealed therapeutic environment can induce macro-strain and micro-strain in the tissue site, as well as remove exudates and other fluids from the tissue site, which can be collected in the container 115 .
  • the fluid mechanics of using a negative-pressure source to reduce pressure in another component or location, such as within a sealed therapeutic environment, can be mathematically complex.
  • the basic principles of fluid mechanics applicable to negative-pressure therapy are generally well-known to those skilled in the art, and the process of reducing pressure may be described illustratively herein as “delivering,” “distributing,” or “generating” negative pressure, for example.
  • exudates and other fluids flow toward lower pressure along a fluid path.
  • downstream typically implies something in a fluid path relatively closer to a source of negative pressure or further away from a source of positive pressure.
  • upstream implies something relatively further away from a source of negative pressure or closer to a source of positive pressure.
  • outlet or outlet in such a frame of reference. This orientation is generally presumed for purposes of describing various features and components herein.
  • the fluid path may also be reversed in some applications (such as by substituting a positive-pressure source for a negative-pressure source) and this descriptive convention should not be construed as a limiting convention.
  • the controller 120 may receive and process data from one or more sensors, such as the first sensor 125 .
  • the controller 120 may also control the operation of one or more components of the therapy system 100 to manage the pressure delivered to the tissue interface 135 .
  • controller 120 may include an input for receiving a desired target pressure, and may be programmed for processing data relating to the setting and inputting of the target pressure to be applied to the tissue interface 135 .
  • the target pressure may be a fixed pressure value set by an operator as the target negative pressure desired for therapy at a tissue site and then provided as input to the controller 120 .
  • the target pressure may vary from tissue site to tissue site based on the type of tissue forming a tissue site, the type of injury or wound (if any), the medical condition of the patient, and the preference of the attending physician.
  • the controller 120 can operate the negative-pressure source 105 in one or more control modes based on the target pressure, and may receive feedback from one or more sensors to maintain the target pressure at the tissue interface 135 .
  • the manifold 405 may have distinct pressure zones, and different target pressures and control modes may be applied to different pressure zones.
  • system 100 can also reduce edema and bruising in a broader area adjacent to an incision.
  • the dressing 110 can reduce stress on an incision and maximize coverage area of articulating joints, while still allowing for range of motion.
  • the dressing 110 can also be beneficial for managing edema and bruising of tissue sites without an incision or open wound, such as a sprain.
  • the features of the dressing 110 may allow an area to be treated for up to 14 days without changing the dressing 110 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Surgical Instruments (AREA)
US16/166,424 2017-10-23 2018-10-22 Area management of tissue sites on articulating joints Pending US20190117466A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/166,424 US20190117466A1 (en) 2017-10-23 2018-10-22 Area management of tissue sites on articulating joints

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762575961P 2017-10-23 2017-10-23
US16/166,424 US20190117466A1 (en) 2017-10-23 2018-10-22 Area management of tissue sites on articulating joints

Publications (1)

Publication Number Publication Date
US20190117466A1 true US20190117466A1 (en) 2019-04-25

Family

ID=63965249

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/166,424 Pending US20190117466A1 (en) 2017-10-23 2018-10-22 Area management of tissue sites on articulating joints
US16/757,642 Pending US20200330285A1 (en) 2017-10-23 2018-10-23 Area management of tissue sites on articulating joints

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/757,642 Pending US20200330285A1 (en) 2017-10-23 2018-10-23 Area management of tissue sites on articulating joints

Country Status (7)

Country Link
US (2) US20190117466A1 (zh)
EP (3) EP3473218B1 (zh)
JP (2) JP7333316B2 (zh)
CN (2) CN115645640A (zh)
AU (1) AU2018355151B2 (zh)
CA (1) CA3079511A1 (zh)
WO (2) WO2019083872A1 (zh)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116884B2 (en) 2010-12-08 2021-09-14 Convatec Technologies Inc. Integrated system for assessing wound exudates
US11135315B2 (en) 2010-11-30 2021-10-05 Convatec Technologies Inc. Composition for detecting biofilms on viable tissues
CN113811272A (zh) * 2019-05-13 2021-12-17 凯希特许有限公司 具有策略性形状的允许进行增强关节运动的敷料
US11241525B2 (en) 2010-12-08 2022-02-08 Convatec Technologies Inc. Wound exudate monitor accessory
US11241339B2 (en) 2011-11-29 2022-02-08 Convatec Inc. Perforated binder for laminated wound dressing
US11266774B2 (en) 2016-07-08 2022-03-08 Convatec Technologies Inc. Fluid collection apparatus
US11286601B2 (en) 2012-12-20 2022-03-29 Convatec Technologies, Inc. Processing of chemically modified cellulosic fibres
US11331221B2 (en) 2019-12-27 2022-05-17 Convatec Limited Negative pressure wound dressing
US11452808B2 (en) 2016-07-08 2022-09-27 Convatec Technologies Inc. Fluid flow sensing
US11458044B2 (en) 2008-09-29 2022-10-04 Convatec Technologies Inc. Wound dressing
US20220379003A1 (en) * 2019-11-01 2022-12-01 Kci Licensing, Inc. Dressing with area management for extremities
EP3965709A4 (en) * 2019-05-07 2023-01-11 Aroa Biosurgery Limited NEGATIVE PRESSURE DRESSING
US11583430B2 (en) 2011-09-02 2023-02-21 Convatec Ltd. Skin contact material
US11596554B2 (en) 2016-07-08 2023-03-07 Convatec Technologies Inc. Flexible negative pressure system
US11628093B2 (en) 2008-05-08 2023-04-18 Convatec Technologies, Inc. Wound dressing
US11723808B2 (en) 2016-03-30 2023-08-15 Convatec Technologies Inc. Detecting microbial infections in wounds
US11740241B2 (en) 2016-03-30 2023-08-29 Synovo Gmbh Construct including an anchor, an enzyme recognition site and an indicator region for detecting microbial infection in wounds
US11771819B2 (en) 2019-12-27 2023-10-03 Convatec Limited Low profile filter devices suitable for use in negative pressure wound therapy systems
US11833290B2 (en) * 2019-11-01 2023-12-05 Kci Licensing, Inc. Dressing design incorporating formed 3D textile for the delivery of therapeutic negative pressure and compressive forces to a treatment site
US12076215B2 (en) 2019-06-03 2024-09-03 Convatec Limited Methods and devices to disrupt and contain pathogens
US12121645B2 (en) 2020-08-17 2024-10-22 Convatec Technologies Inc. Method and system for removing exudates from a wound site

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020231508A1 (en) * 2019-05-13 2020-11-19 Kci Licensing, Inc. Dressing allowing enhanced articulation with strategic welds
WO2022084771A1 (en) * 2020-10-21 2022-04-28 Kci Manufacturing Unlimited Company Customizable dressing with integrated bridge
WO2023092202A1 (pt) * 2021-11-24 2023-06-01 Moreira Costa De Souza Gustavo Curativo para terapia de feridas com pressão negativa

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160045375A1 (en) * 2012-01-18 2016-02-18 Worldwide Innovative Healthcare, Inc. Modifiable Occlusive Skin Dressing

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5344415A (en) * 1993-06-15 1994-09-06 Deroyal Industries, Inc. Sterile system for dressing vascular access site
FR2736540B1 (fr) * 1995-07-12 1998-01-16 Paccalet Marie Christine Protection destinee a prevenir les escarres
US6190344B1 (en) * 1998-11-12 2001-02-20 Adbme Enterprises Inc. Orthopaedic support fastening system
US6402712B1 (en) * 1999-08-16 2002-06-11 Cho-Pat, Inc. Dual action knee strap
US20050147656A1 (en) * 2001-06-14 2005-07-07 Hemcon, Inc. Tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan
US7896827B2 (en) * 2004-12-22 2011-03-01 Ossur Hf Knee brace and method for securing the same
JP2009509574A (ja) * 2005-09-26 2009-03-12 コロプラスト アクティーゼルスカブ 被覆材
CN200969875Y (zh) * 2006-11-02 2007-11-07 彪仕医技股份有限公司 扣合式保健髌骨护膝
US7837638B2 (en) * 2007-02-13 2010-11-23 Coolsystems, Inc. Flexible joint wrap
JP2008245989A (ja) * 2007-03-30 2008-10-16 Tokyo Health Hanbai:Kk 膝サポーター
CN103417332B (zh) * 2008-05-30 2015-10-07 凯希特许有限公司 超吸收性减压伤口敷料和系统
AU2010310467B2 (en) * 2009-10-22 2015-08-27 Coolsystems, Inc. Temperature and flow control methods in a thermal therapy device
CN201640522U (zh) * 2010-01-11 2010-11-24 红崴科技股份有限公司 护膝
US8469913B1 (en) * 2010-06-16 2013-06-25 Albahealth, LLC Injured limb protector
US20120109034A1 (en) 2010-10-27 2012-05-03 Kci Licensing, Inc. Interactive, wireless reduced-pressure dressings, methods, and systems
US9107990B2 (en) * 2011-02-14 2015-08-18 Kci Licensing, Inc. Reduced-pressure dressings, systems, and methods for use with linear wounds
CA2864428A1 (en) * 2012-03-28 2013-10-03 Kci Licensing, Inc. Reduced-pressure systems, dressings, and methods facilitating separation of electronic and clinical component parts
EP3741347B1 (en) 2013-03-12 2024-07-10 Solventum Intellectual Properties Company System utilizing vacuum for promoting the healing of sprains
US20160120706A1 (en) * 2013-03-15 2016-05-05 Smith & Nephew Plc Wound dressing sealant and use thereof
US9827132B2 (en) * 2013-05-31 2017-11-28 Mueller Sports Medicine, Inc. Elbow brace
KR101527767B1 (ko) * 2013-12-05 2015-06-12 신천재 관절보호대
JP2017525860A (ja) * 2014-06-25 2017-09-07 ミューラー スポーツ メディシン インコーポレイテッド 膝装具
EP3669840B1 (en) * 2015-11-20 2022-12-28 3M Innovative Properties Company Medical system with flexible fluid storage bridge
CN205698232U (zh) * 2016-04-11 2016-11-23 浙江隆泰医疗科技股份有限公司 异形硅凝胶泡沫敷料
WO2018212849A1 (en) * 2017-05-16 2018-11-22 Kci Licensing, Inc. An absorbent negative-pressure dressing system for use with post-surgical breast wounds
US11850124B2 (en) * 2017-10-24 2023-12-26 3M Innovative Properties Company Debridement wound dressings and systems and methods using the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160045375A1 (en) * 2012-01-18 2016-02-18 Worldwide Innovative Healthcare, Inc. Modifiable Occlusive Skin Dressing

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11628093B2 (en) 2008-05-08 2023-04-18 Convatec Technologies, Inc. Wound dressing
US11458044B2 (en) 2008-09-29 2022-10-04 Convatec Technologies Inc. Wound dressing
US11135315B2 (en) 2010-11-30 2021-10-05 Convatec Technologies Inc. Composition for detecting biofilms on viable tissues
US11241525B2 (en) 2010-12-08 2022-02-08 Convatec Technologies Inc. Wound exudate monitor accessory
US11116884B2 (en) 2010-12-08 2021-09-14 Convatec Technologies Inc. Integrated system for assessing wound exudates
US11583430B2 (en) 2011-09-02 2023-02-21 Convatec Ltd. Skin contact material
US11241339B2 (en) 2011-11-29 2022-02-08 Convatec Inc. Perforated binder for laminated wound dressing
US11286601B2 (en) 2012-12-20 2022-03-29 Convatec Technologies, Inc. Processing of chemically modified cellulosic fibres
US11740241B2 (en) 2016-03-30 2023-08-29 Synovo Gmbh Construct including an anchor, an enzyme recognition site and an indicator region for detecting microbial infection in wounds
US11723808B2 (en) 2016-03-30 2023-08-15 Convatec Technologies Inc. Detecting microbial infections in wounds
US11266774B2 (en) 2016-07-08 2022-03-08 Convatec Technologies Inc. Fluid collection apparatus
US11596554B2 (en) 2016-07-08 2023-03-07 Convatec Technologies Inc. Flexible negative pressure system
US11452808B2 (en) 2016-07-08 2022-09-27 Convatec Technologies Inc. Fluid flow sensing
EP3965709A4 (en) * 2019-05-07 2023-01-11 Aroa Biosurgery Limited NEGATIVE PRESSURE DRESSING
CN113811272A (zh) * 2019-05-13 2021-12-17 凯希特许有限公司 具有策略性形状的允许进行增强关节运动的敷料
US12076215B2 (en) 2019-06-03 2024-09-03 Convatec Limited Methods and devices to disrupt and contain pathogens
US20220379003A1 (en) * 2019-11-01 2022-12-01 Kci Licensing, Inc. Dressing with area management for extremities
US11833290B2 (en) * 2019-11-01 2023-12-05 Kci Licensing, Inc. Dressing design incorporating formed 3D textile for the delivery of therapeutic negative pressure and compressive forces to a treatment site
US11331221B2 (en) 2019-12-27 2022-05-17 Convatec Limited Negative pressure wound dressing
US11771819B2 (en) 2019-12-27 2023-10-03 Convatec Limited Low profile filter devices suitable for use in negative pressure wound therapy systems
US12121645B2 (en) 2020-08-17 2024-10-22 Convatec Technologies Inc. Method and system for removing exudates from a wound site

Also Published As

Publication number Publication date
EP3473218B1 (en) 2021-09-01
EP3700483A1 (en) 2020-09-02
CN115645640A (zh) 2023-01-31
EP3473218A1 (en) 2019-04-24
JP7333316B2 (ja) 2023-08-24
WO2019083979A1 (en) 2019-05-02
WO2019083872A1 (en) 2019-05-02
AU2018355151B2 (en) 2024-09-19
JP7510544B2 (ja) 2024-07-03
JP2023120311A (ja) 2023-08-29
CN111356425B (zh) 2022-10-11
JP2021500141A (ja) 2021-01-07
CA3079511A1 (en) 2019-05-02
CN111356425A (zh) 2020-06-30
EP3936094A1 (en) 2022-01-12
AU2018355151A1 (en) 2020-05-07
US20200330285A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
AU2018355151B2 (en) Area management of tissue sites on articulating joints
US20240325210A1 (en) High-density evaporative bridge dressing
US12097093B2 (en) Dressing bolster with area pressure indicator
EP3681549B1 (en) Oxygen therapy with fluid removal
EP3813750B1 (en) Release liner with edge protection
US20220355021A1 (en) Long-Term Wear Tissue Interfaces For High-Closure Force Negative- Pressure Therapy Dressings
US20220379003A1 (en) Dressing with area management for extremities
US11779693B2 (en) Negative-pressure wound therapy dressing with zone of ambient pressure
EP3784182A1 (en) Dressing providing apertures with multiple orifice sizes for negative-pressure therapy
WO2021220100A1 (en) Dressing with rolled configuration

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

AS Assignment

Owner name: KCI LICENSING, INC., TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KAZALA, RICHARD MARVIN;RANDOLPH, LARRY TAB;PERKINS, LUKE;AND OTHERS;SIGNING DATES FROM 20220715 TO 20220722;REEL/FRAME:060599/0158

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

AS Assignment

Owner name: 3M INNOVATIVE PROPERTIES COMPANY, MINNESOTA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KCI LICENSING, INC.;REEL/FRAME:064788/0823

Effective date: 20230830

AS Assignment

Owner name: 3M INNOVATIVE PROPERTIES COMPANY, MINNESOTA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION LISTED ON SCHEDULE OF IP RIGHTS ATTACHED TO ASSIGNMENT AT LINES 55: 71; 89; 116-129; AND 131 NEED TO BE DELETED PREVIOUSLY RECORDED AT REEL: 064788 FRAME: 0823. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:KCI LICENSING, INC.;REEL/FRAME:064886/0479

Effective date: 20230830

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

AS Assignment

Owner name: SOLVENTUM INTELLECTUAL PROPERTIES COMPANY, MINNESOTA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:3M INNOVATIVE PROPERTIES COMPANY;REEL/FRAME:066436/0225

Effective date: 20240201

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED